Luzheng Xue

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7201218/publications.pdf

Version: 2024-02-01

516710 642732 2,443 23 16 23 h-index citations g-index papers 26 26 26 3715 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis. Journal of Experimental Medicine, 2013, 210, 2939-2950.	8.5	803
2	Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. Journal of Allergy and Clinical Immunology, 2014, 133, 1184-1194.e7.	2.9	433
3	Prostaglandin D2 Causes Preferential Induction of Proinflammatory Th2 Cytokine Production through an Action on Chemoattractant Receptor-Like Molecule Expressed on Th2 Cells. Journal of Immunology, 2005, 175, 6531-6536.	0.8	229
4	Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. Journal of Experimental Medicine, 2016, 213, 2399-2412.	8.5	194
5	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	28.9	164
6	Cysteinyl leukotriene E 4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D 2 and epithelial cytokines. Journal of Allergy and Clinical Immunology, 2017, 140, 1090-1100.e11.	2.9	130
7	Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production. Journal of Immunology, 2016, 196, 45-54.	0.8	73
8	Novel Function of CRTH2 in Preventing Apoptosis of Human Th2 Cells through Activation of the Phosphatidylinositol 3-Kinase Pathway. Journal of Immunology, 2009, 182, 7580-7586.	0.8	70
9	Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. Journal of Allergy and Clinical Immunology, 2015, 135, 1358-1366.e11.	2.9	50
10	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. Mucosal Immunology, 2018, 11, 1408-1419.	6.0	46
11	Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. Therapeutic Advances in Respiratory Disease, 2015, 9, 135-145.	2.6	39
12	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	4.7	39
13	Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D2. Biochemical Pharmacology, 2007, 73, 843-853.	4.4	38
14	Leukotriene E4 Activates Human Th2 Cells for Exaggerated Proinflammatory Cytokine Production in Response to Prostaglandin D2. Journal of Immunology, 2012, 188, 694-702.	0.8	36
15	Neuromedin U: potential roles in immunity and inflammation. Immunology, 2021, 162, 17-29.	4.4	27
16	Novel data analysis method for multicolour flow cytometry links variability of multiple markers on single cells to a clinical phenotype. Scientific Reports, 2017, 7, 5471.	3.3	20
17	Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. Journal of Allergy and Clinical Immunology, 2019, 143, 2329-2333.	2.9	11
18	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. Journal of Immunology, 2021, 206, 2714-2724.	0.8	8

Luzheng Xue

#	ARTICLE	IF	CITATION
19	Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells. Journal of Allergy and Clinical Immunology, 2019, 144, 1722-1726.e10.	2.9	5
20	Neuromedin U promotes human type 2 immune responses. Mucosal Immunology, 2022, 15, 990-999.	6.0	5
21	Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 745-747.	2.9	4
22	Evaluation of perturbed iron-homeostasis in a prospective cohort of patients with COVID-19. Wellcome Open Research, 0, 7, 173.	1.8	4
23	Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy, Asthma and Clinical Immunology, 2021, 17, 67.	2.0	3